"Pioneering brain and mind clinic specialising in the diagnosis, treatment and ongoing care of individuals showing symptoms of cognitive impairment or mental health concerns"

During the past decade, Re:Cognition Health conducted 16 clinical trials. In the 10-year time frame, 16 clinical trials started and 4 clinical trials were completed, i.e. on average, 25% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 2 clinical trials were completed. i.e. 25% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Re:Cognition Health" #1 sponsor was "Hoffmann-La Roche" with 4 trials, followed by "Novoic Limited" with 3 trials sponsored, "Anavex Life Sciences Corp." with 2 trials sponsored, "AstraZeneca" with 2 trials sponsored and "Eli Lilly and Company" with 2 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Re:Cognition Health" #1 collaborator was "Anavex Australia Pty Ltd." with 2 trials as a collaborator, "Anavex Germany GmbH" with 2 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator, "Amsterdam UMC, location VUmc" with 1 trials as a collaborator and "Anavex Canada Ltd." with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Re:Cognition Health" are "Alzheimer Disease" (11 trials), "Alzheimer's Disease (Incl Subtypes)" (3 trials), "Mild Cognitive Impairment" (3 trials), "Preclinical Alzheimer's Disease" (3 trials) and "Prodromal Alzheimer's Disease" (3 trials). Many other conditions were trialed in "Re:Cognition Health" in a lesser frequency.

Most popular intervention types in "Re:Cognition Health" are "Drug" (13 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Gantenerumab" (4 trials), "Lanabecestat" (2 trials), "ANAVEX2-73" (1 trials) and "Donanemab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Re:Cognition Health" are 16 trials for "All" genders.

Currently, there are NaN active trials in "Re:Cognition Health". undefined are not yet recruiting, 2 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Re:Cognition Health, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Re:Cognition Health, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".